Trial Profile
An Open-Label, Multicenter, Single-Arm, Phase II Study to Assess the Efficacy and Safety of Alectinib in Patients With ALK-Rearranged Non-Small Cell Lung Cancer After Disease Progression on Prior ALK Inhibitor Therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Alectinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms ATALK
- Sponsors Roche
- 31 Jan 2021 Results presented at the 2020 World Conference on Lung Cancer
- 19 Nov 2020 Results of a secondary endpoint analysis assessing the health related Quality of Life, presented at the 23rd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
- 23 Oct 2019 Status changed from active, no longer recruiting to completed.